Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

Inventors

Cai, Xiong • Zhai, Haixiao • Lai, Chengjung • Qian, Chenggeng

Assignees

Curis Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10336770-B2

Patent

Publication Date

2019-07-02

Expiration Date


Abstract

The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

Core Innovation

The disclosure provides zinc-binding deazapurine, thienopyrimidine, furopyrimidine, and benzothiophene derivatives represented by formula (II), or pharmaceutically acceptable salts thereof. The scaffold defines ring atoms X and Y independently selected from CR1, N(R8), S, or O, with a single or double bond, an oxygen G1 group, an aryl, heteroaryl, or heterocyclic G2 group, a linker B, and a depicted C group wherein R33 is hydrogen. Disclosed embodiments incorporate morpholine, indazole, or related fused heteroaryl groups alongside hydroxamic acid or N-hydroxyamide moieties.

The compounds exhibit integrated dual PI3K and HDAC inhibitory activity, with certain embodiments further inhibiting mTOR or MMP through zinc coordination. In addition, the compounds demonstrate antiproliferative effects across multiple cancer cell lines. This multi-target mechanism addresses resistance and therapeutic limitations associated with single-target PI3K inhibition in disorders mediated by PI3K, HDAC, or both.

Claims Coverage

The claims define one independent claim, claim 1, comprising four inventive features directed to a compound of formula (II) or a pharmaceutically acceptable salt thereof.

Formula (II) compound or pharmaceutically acceptable salt

A compound represented by formula (II), or a pharmaceutically acceptable salt thereof.

Specified ring atoms and substituents

The specified bond represents a single or double bond, and X and Y are independently CR1, N(R8), S, or O, with the proviso that when one of X and Y is CR1, the other is N(R8), S, or O. R1 is selected from hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF3, CN, NO2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; each R8 is independently hydrogen, acyl, aliphatic, or substituted aliphatic.

Oxygen G1 and specified G2 groups

G1 is O, and G2 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclic.

Linker B and depicted group C

B is a linker, and C is the depicted structure wherein R33 is hydrogen.

Claim 1 encompasses the formula (II) structural genus and its pharmaceutically acceptable salts defined by limitations on the ring bond, ring atoms, substituents, G1 and G2 groups, linker B, and depicted group C.

Stated Advantages

Integrated dual PI3K and HDAC activity is presented as potentially synergistic.

The integrated activity is presented as a way to address resistance and limitations of single-target PI3K inhibition.

Documented Applications

A pharmaceutical composition comprising the compound of formula (II), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Treatment of a disease mediated by PI3K, HDAC, or both targets using a therapeutically effective amount of the pharmaceutical composition.

Therapeutic use for hematologic and solid cancers, and other disorders associated with aberrant cell proliferation or dysregulation of PI3K, HDAC, or mTOR.

Treatment of autoimmune and inflammatory disorders, neurodegenerative diseases, and transplant-related immune responses.

Reducing circulating lymphocyte counts, immune modulation, apoptosis regulation, and combination therapy with anticancer agents or radiation.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.